Member Info for Sandhopper

If the Directors have sold any shares then they will have to advise the Market and we will see an RNS. Personally I don't think the Directors would be so stupid to sell right away after stitching up the shareholders on that eventful night .

I had read some time ago that the Administrators of the Woodford Funds may try and sell more of the Woodford shares by early July in order to give the old Woodford Funds holders another pay out of cash, so maybe it could be that. Not sure of how much of his holdings in TRX are still left to be sold.

Hi chester,
sorry for the late reply mate, I have had to catch up on some sleep as only had 1 hour sleep in the last 2 days - my disabled wife had a medical issue, but that's all sorted now thankfully.

Yes, agree the B.O.D. now have all their Resolutions passed at the AGM, they also have money in the Pot to address the products supply issues as well. Let's hope CV-19 both here and in the USA won't delay them too much.

Now can we please get the BUS we have all piled into, out of Reverse, and gradually up through the gears into 4th/5th going forward.

Leeds, 30 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group") the regenerative medical devices company, provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

So let's hope that now the company have got their resolutions passed giving them some surety, they can turn around and update us small pi's with some positive news which will get this share price moving in the right direction once more. GLA.

RNS Number : 4427R
Shearwater Group PLC
30 June 2020

SHEARWATER GROUP PLC
("Shearwater", or the "Group")

Notice of Results

Shearwater Group plc (AIM: SWG), the organisational resilience group that provides cybersecurity, advisory and managed security services, announces that its audited final results for the year ended 31 March 2020 (FY20) will be released in late July 2020.

Whilst the audit of the FY20 Results is well advanced, the disruption caused by remote working restrictions in response to COVID-19 has delayed the Company's auditors' ability to finalise their work. The Board looks forward to announcing audited underlying FY20 EBITDA(1) in excess of GBP3m later next month, in line with our April Trading Update.

Note 1. Underlying EBITDA defined as profit before tax, before one off exceptional items, share based payment charges, finance charges, depreciation and amortisation.

Welcome to the board Hanger66. Agree that several of us LTH's feelings are 'reflective' of your own, with our investment history in TRX also very much the same as yourself, buying all the way down from over 20p as we seen the potential this company possesses.

The company "could have, should have, and would have" been in a better position if it had the right management in place long ago. However, let's hope this recent placing fiasco will lead to the company being able to firstly survive, and now take advantage of the massive opportunities that have presented themselves, to grow maybe into a successful world leading authority in the arena of the Bio Tech Science they are, and have, made themselves known.

G.L.A.

Very good summary chester.

Missed the action mid morning and this afternoon as after an appointment, took the 'mrs' for a bit of a jaunt across "Sedgemoor, then up through Cheddar Gorge, across top of Mendip, and down through Burrington Coombe past the Rock of Ages"

The good bit was, I topped up with a small 126,000 plus @ 3.098p this morning before being tied up for the rest of today until now - time for the top of that Glenmorangie Tarlogan to be loosened tonight me thinks.

Tried to top-up with a small 125K+ shares this morning when the sp was 30/31, but Hargreaves platform said I didn't have the funds to make a purchase even though I had more than enough. When the sp went up later then all of a sudden I could buy at a higher price. Will wait and see where we are later in the day.

milnrowmug, re your question - we had 1,172 Million shares in issue before the fundraising etc, now we are going to have another 5,859,626,212 new Ordinary Shares issued pursuant to this recent fundraising @ 0.25p. Add together both amounts to get the overall shares that will be in issue New Total will be 7,031 Million +. Because the new shares being added have been purchased at a 76% discount to the price the shares were at when the fundraising was announced, then this is most likely to bring the total shares in issue down to somewhere near the placing price +/- to what the market makers deem appropriate. Watch closely over the next week or so...….

...are not yet added to the sum total of shares in issue - when they are, that's when we will see the real drop.

Who is selling 56,250,000 shares - be nice to learn it might be Link. The sooner their shares are gone, the better.

Morning chester / Stu,

I agree with you both about the board being subdued after the surprise of a placing with a 76% discount, but only if you had looked in during that 4 hour period after the close of market that unforgettable evening, and also had cash available and were signed up with PrimaryBid so you could take advantage. Now we have a General Meeting that no pi can go to due to "social distancing". You couldn't really make it up could you ?

chester, we each bought a bottle of more expensive than usual Glenmorangie before the awful news to celebrate the funding being sorted when it was announced, well I don't know about you but although by Tuesday just after 12 noon the "rubber stamp" is almost certain to be employed, I don't think I will have the euphoria to be "cracking open" my bottle even though the company will have no cash worries for the immediate future.

Maybe I will celebrate opening my bottle when break even on my investment here happens, but do I want to wait a possible couple of years !! chester, I don't expect you want to wait for your 18 year old whiskey to be a 20 year old whiskey either before you demolish it !!

Anyway Guys, what's done is done (almost) so we all have to accept it and be pleased our investment here still has a future - GLA.

tom111 - you mention "if you had bought 3 years ago", well there are a few of us on this board that have been here longer than that. Me personally, I still have shares bought at just a tad under 21p - ooouuuccchhh, but have kept the faith most probably because I believe in the product(s) and never thought I would ever see these prices we are experiencing now.

When I read some posts that state they have bought their shares at between 1p / 1.5p and they are cringing it might take them another 12 / 24 months to get their money back, and then those who have stated they have a beak-even of less than a 1p, I think "If only I was so lucky".

I still believe this company IF it has the right B.O.D, and is managed correctly, including looking after the shareholders, and not just managed to fill their own deep pockets, then it has a fantastic future. Look at the patented products being produced that are in demand, the 'contacts in right places' to distribute those products etc, etc. The infrastructure is in place - so manage it correctly and let's all get rich !!

Gareth Jones, Interim CEO of Tissue Regenix Group, commented:

"During 2019, recognising the need to optimise our supply chain and processes to address various operational challenges and support the growing demand for our products, we concentrated efforts on implementing a number of efficiency improvements which manifested in donor throughput more than doubling between Q1-Q4 2019 at the facility in San Antonio. Despite experiencing manufacturing capacity constraints and operational challenges, these initiatives meant we were able to increase our top-line revenue by 12% year-on-year (8% constant currency). In conjunction with this we implemented a number of cost control measures in Q4 2019 which will provide annualised savings of circa. GBP1m. We remain committed to assessing our ongoing operational cost base to ensure that funds are deployed in the most efficient manner and efficiencies maximised, as we work towards a position of break-even. In May 2020, we undertook a fundraise of GBP14.62m, subject to approval by shareholders at a General Meeting and admission of shares on AIM, to invest in our manufacturing infrastructure to increase this capacity further which will allow us to unlock additional revenues and new partnership opportunities.

As an example of the exciting growth potential of the business and testament to the strong underlying demand for our portfolio of regenerative biologic products, following the year-end, we announced a strategic partnership with a top 10 global healthcare company for a new product launch. Additionally, the receipt of CE Mark approval for OrthoPure XT is a significant milestone in the evolution of our product portfolio and corporate objectives.

We remain confident in our long-term strategy to grow the business. However, whilst sales were not materially impacted during Q1 2020, where we delivered 18% year-on-year growth, the Board is unable to provide clarity on the financial outlook for 2020 until there is greater visibility around the impact of the COVID-19 pandemic in the market."

Annual results for the year ended 31 December 2019
and
Notice of AGM
Revenue up 12% year-on-year (8% constant currency)

Fundraising of gross proceeds of GBP14.62m subject to shareholder approval at a General Meeting

Leeds, 5 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix", the "Company" or the "Group"), the regenerative medical devices company, today announces its annual results for the year ended 31 December 2019.

Financial highlights
-- Increased revenues by 12% (8% constant currency) to GBP13.03m (2018: GBP11.62m)

o BioSurgery sales of dCELL(R) products sales increased by 25% to GBP4.23m (2018: GBP3.38m)

o Orthopaedics and Dental sales of BioRinse products grew by 5% to GBP6.72m

(2018: GBP6.40m)

o Joint venture GBM-v sales grew by13% to GBP2.08m (2018: GBP1.84m)
-- Gross profit increased to GBP6.02m (2018: GBP5.92m)
-- Operating loss narrowed to GBP7.20m (2018: GBP8.69m)

-- Drawdown of $2m of the MidCap Financial Term Loan, with access to a $3m Revolving Credit Facility as at 31 December 2019

-- Net cash at 31 December 2019 of GBP2.38m (2018: GBP7.82m), including GBP1m of the MidCap Revolving Credit Facility

Operational highlights

-- Strengthened the San Antonio management team, including establishing a specialist Donor Services team
-- Orthopaedic donor throughput more than doubled between Q1-Q4 2019
-- Commenced a second shift in the San Antonio facility
-- Outsourced certain product lines to increase manufacturing capacity

-- Lease signed on additional 21,000sq ft manufacturing facility in San Antonio, which subject to securing financing is ready to commence clean room fit out
-- Soft launch of DermaPure non-oriented product for surgical and urogynaecology applications

-- Further Group Purchasing Organisation (GPO) approvals for DermaPure, increasing coverage to c.95% of US GPO hospitals

Post period highlights

-- Q1 revenue increased by 18% year-on-year, despite cyberattack experienced at San Antonio facility

-- Conditional fundraising raised gross proceeds of GBP14.62m announced on 22 May, subject to shareholder approval at a General Meeting on 9 June and admission of shares to AIM

-- New strategic collaboration with a top 10 global healthcare company for a newly developed product line was announced on 11 May 2020

-- US Government backed loans of $1m secured in April 2020 to assist with US cost base during COVID-19 pandemic
-- Award of CE Mark for OrthoPure XT announced on 1 June 2020

Gareth Jones, Interim CEO of Tissue Regenix Group, commented:

"During 2019, recognising the need to optimise our supply chain and processes to address various operational challenges and support the growing demand for our products, we concentrated efforts on implementing a number of efficiency improvements which manifested in donor throughput more than doubling between Q1-Q4 2019

...are that when the new shares are added to our current issued share total in two weeks time we will / will have seen a drop in the shares price to near that of the recent “fiasco of a placing”- reasons being the company are issuing multiple more shares than are currently in issue.

I would have liked to participate in the recent “fiasco” but could not get the funds together within the few hours available after reading the RNS. I now have the funds available, and yes I intend to add more shares but feel waiting for another two weeks then they will be cheaper than today.

I want to “round-up” both my ISA and the Ordinary account in anticipation of the inevitable consolidation that will follow, which I don’t think would be too long after. My guess as to what size the consolidation would be, then either 50:1 or most probably 100:1

Just my thoughts whilst we wait for another two weeks re the results of the General Meeting, which I would say is a foregone conclusion.

RNS Number : 9069N

Tissue Regenix Group PLC

26 May 2020

Tissue Regenix Group plc

("Tissue Regenix", the "Group" or the "Company")

Publication of circular and notice of General Meeting

Tissue Regenix announces that a circular containing further information on its recent fundraise (the "Circular") was posted to Shareholders on Friday 22 May. The Circular also contains a notice of General Meeting (the "General Meeting") and accompanying form of proxy.

The General Meeting will be held at the offices of Squire Patton Boggs (UK) LLP, 6 Wellington Place, Leeds at 12 noon on 9 June 2020.

The UK Government passed into law mandatory measures in order to reduce the transmission of COVID-19. These mandatory measures prohibit, amongst other things, individuals engaging in non-essential travel and public gatherings of more than two people, save where the gathering is essential for work purposes (the "Stay at Home Measures").

The Company is required to hold the General Meeting in order to implement the planned fundraise. However the Stay at Home Measures will significantly restrict our ability to follow a standard shareholder meeting format. In order to ensure shareholders can comply with the Stay at Home Measures the Board has concluded that shareholders should not plan to attend the General Meeting in person. It is currently intended that the General Meeting will be held with only the minimum number of shareholders present as required to form a quorum under the Company's Articles of Association, and who are essential for the business of the General Meeting to be conducted.

The results of the votes on the proposed resolutions will be announced in the normal way as soon as practicable after the conclusion of the General Meeting.

Having regard to their own safety and that of others, shareholders are respectfully asked to comply with the Stay at Home Measures and not make plans to attend the General Meeting. To ensure the safety of the limited number of people whose attendance is essential, the Company will not be able to allow other shareholders to gain access to the General Meeting on the day. Given the restrictions on travel and as to how the meeting itself may be conducted, shareholders are strongly encouraged to exercise their right to vote and to submit a proxy as early as possible.

The Circular, notice of General Meeting and accompanying form of proxy, are also available on the Company's website, www.tissueregenix.com, in accordance with AIM Rule 20.

From the RNS:

At the General Meeting there will be no pi shareholders allowed due to the current Government ruling on social distancing. We can of course complete “form of proxy” but with no current Chairman it would be the CEO that they go to, so we all know how our voting would be ‘administered’.

From past experience, shareholders who have their shares via a Nominee Broker (i.e. Hargreaves Lansdown) would not receive Forms of Proxy from TRX, as they would be sent to the Broker. When I have contacted my Broker for such forms I was told, quote, “we have so many pi’s it is not economical for us to send out Forms of Proxy – so we don’t) and anyway with only a skeleton staff working at the moment it would be a definite no-no.

Happy Voting guys !!

There are some of us who have been invested here for a few years (me - 5 years now) and some of us have aired our dis-pleasures by emailing the company without getting any replies.

I would love to be at the General Meeting on June 9th to personally fire a few "salvo's" at the Board at their handling of this recent fiasco of a "fund raising". Unfortunately living 260 miles away and being a 24/7 carer for my 100% disabled wife, would not allow me to get there.

As has be said on this board before, the Directors knew what they were going to be doing, so have had time to “position” themselves to take advantage for buying placing shares @ 0.25p. The loyal shareholders that the B.O.D. have “in their best interests” so they say, now seem to be “fc*k you jack shareholder, we are alright”

Silverfox333, I am sorry to hear your experience and I can personally relate to it, (lost £250K eleven years ago here on AIM) and I'm sure there are many, many, more pi's whom have all travelled down this same road. You must try and put the AIM experience behind you and think of the positives you have in life. As you have said, you have a decent pension, which is more than some people have been left with after they have lost everything on AIM. Be careful even if you continue investing with FTSE 100 / 250 / 350 shares as there have been big losers there also, albeit the companies on those markets are usually run by more experienced, professional, and successful BOD's than here on AIM. Even the most careful research does not always stop you loosing your hard earned money. Remember, life is like a book of several chapters, so let's hope you turn over the page and the next few chapters are better than the chapter you have just experienced. Good Luck to you for the future.

I have just done a "bed & ISA" both at the same price - 0.446, so we don't know which are buys and which might be sells !!